Wafra Investment Advisory Group Inc. NY cut its holdings in Celgene Co. (NASDAQ:CELG) by 9.3% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 159,921 shares of the biopharmaceutical company’s stock after selling 16,453 shares during the quarter. Celgene makes up 1.1% of Wafra Investment Advisory Group Inc. NY’s portfolio, making the stock its 10th largest position. Wafra Investment Advisory Group Inc. NY’s holdings in Celgene were worth $20,769,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in CELG. Neuberger Berman Group LLC increased its position in Celgene by 4.0% in the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock worth $229,553,000 after purchasing an additional 71,729 shares during the period. Grisanti Capital Management LLC acquired a new stake in Celgene in the second quarter worth about $3,616,000. Lincoln Capital Corp increased its position in Celgene by 0.6% in the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock worth $3,971,000 after purchasing an additional 185 shares during the period. RiverPoint Capital Management LLC increased its position in Celgene by 3.1% in the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock worth $15,799,000 after purchasing an additional 3,680 shares during the period. Finally, Russell Investments Group Ltd. increased its position in Celgene by 9.2% in the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock worth $83,344,000 after purchasing an additional 54,210 shares during the period. Institutional investors own 80.16% of the company’s stock.

In other news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.95% of the company’s stock.

A number of brokerages recently commented on CELG. Piper Jaffray Companies reiterated a “hold” rating on shares of Celgene in a research report on Sunday. Cantor Fitzgerald set a $112.00 price objective on Celgene and gave the stock a “hold” rating in a research report on Monday. Atlantic Securities upgraded Celgene from a “neutral” rating to an “overweight” rating in a research report on Friday. Cann reiterated a “buy” rating and issued a $166.00 price objective on shares of Celgene in a research report on Wednesday, November 22nd. Finally, TheStreet lowered Celgene from a “b-” rating to a “c+” rating in a research report on Friday, November 17th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twenty have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $139.57.

Shares of Celgene Co. (CELG) opened at $108.00 on Tuesday. The company has a market capitalization of $83,526.45, a P/E ratio of 16.58, a price-to-earnings-growth ratio of 0.82 and a beta of 1.78. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Co. has a 12 month low of $94.55 and a 12 month high of $147.17.

Celgene (NASDAQ:CELG) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the previous year, the business posted $1.58 EPS. The business’s quarterly revenue was up 10.2% compared to the same quarter last year. equities research analysts expect that Celgene Co. will post 6.67 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/wafra-investment-advisory-group-inc-ny-has-20-77-million-stake-in-celgene-co-celg/1758591.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.